News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
The unprecedented demand for GLP-1 medicines, fuelled by their remarkable ability to help patients shed up to 20% of body weight, has been nothing short of explosive.
Bristol Myers Squibb’s Opdivo was recently granted FDA approval in combination with cisplatin and gemcitabine as a first-line treatment for metastatic urothelial carcinoma (mUC).
Adare Pharma Solutions, a technology-driven CDMO focused on oral dosage forms, is further investing in its Pessano facility in Milan, Italy.